Sophia Genetics

Sophia Genetics SA
Company typePublic
Nasdaq: SOPH
IndustrySoftware
Cloud computing
Founded2011; 13 years ago (2011)
Founders
  • Dr. Jurgi Camblong
  • Prof. Lars Steinmetz
  • Dr. Pierre Hutter
Headquarters
Lausanne, Switzerland
Boston, United States
Key people
  • Dr. Jurgi Camblong (CEO)
  • Ross Muken (CFO)
  • Philippe Menu (CMO)[1]
ServicesSophia DDM Platform
Number of employees
400+
Websitesophiagenetics.com

Sophia Genetics SA is a data-driven medicine software company with headquarters in Lausanne, Switzerland and Boston, Massachusetts.[2][3][4][5] It provides genomic and radiomic analysis for hospitals, laboratories, and biopharma institutions.[6][7]

History

Sophia Genetics was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz in 2011 as a start-up at École Polytechnique Fédérale de Lausanne (EPFL). It began as a research tool for hospitals and federally regulated health care labs, and then expanded to biopharma institutions.[8]

In 2014, the company introduced an analytical software platform, the Sophia DDM Platform (Data-Driven Medicine),[9][10] which helps to interpret circulating tumor DNA and circulating tumour cells in blood, urine, cerebral spinal fluid and other liquid samples.[11] The platform is used for oncology, hereditary cancers, metabolic disorders, pediatrics, cardiology, and for rare disease research.[11]

In 2018, the company set up its first research and development center in France and made acquisition of a France-based molecular biology and genetic analytics software development company, Interactive Biosoftware.[12][13] That same year, Sophia Genetics opened its U.S. headquarters in Boston, Massachusetts.[14]

In August 2020, the company released a data analysis solution that was focused on predicting the disease evolution of the SARS-CoV-2 virus.[15] Also in 2022, the firm began development of a new method for detecting extrachromosomal DNA through collaboration with startup firm Boundless Bio.[1]

In July 2021, Sophia Genetics went public with an IPO backed by J.P. Morgan, Morgan Stanley, and Credit Suisse.[16][17]

Partnership

In 2016, Sophia Genetics entered into a comarketing agreement with Illumina allowing the two companies to promote adoption of next- generation DNA sequencing.[18]

In 2019, Sophia Genetics formed partnerships with Integrated DNA Technologies and Paragon Genomics, next-generation sequencing (NGS) assay development company, to provide COVID-19 test kits[19][20]

In 2021, the company partnered with MGI, a subsidiary of BGI Group, to enable their users to access the SOPHiA DDM Platform for data analysis and interpretation.[21] In March 2021, Sophia Genetics announced a long-term collaboration agreement with Hitachi.[22]

In 2022, the firm committed to a collaboration with Memorial Sloan Kettering Cancer Center to advance predictive tumor analysis and, more broadly, clinical decision support.[1]

References

  1. ^ a b c "Sophia Genetics Partners With MSK on Clinical Decision Support, Boundless Bio on ecDNA Detection". GenomeWeb. 21 September 2022. Retrieved 21 September 2022.
  2. ^ "Sophia Genetics - So Far, So Good..." Nasdaq.
  3. ^ Lomas, Natasha (4 January 2019). "Sophia Genetics bags $77M Series E, with 850+ hospitals signed up to its 'data-driven medicine'". TechCrunch.
  4. ^ Murgia, Madhumita (29 November 2015). "Data-driven medicine: Sophia Genetics becomes largest clinical genomics network". The Daily Telegraph. Retrieved 8 July 2019.
  5. ^ Magistretti, Bérénice (2 January 2017). "Swiss data analytics company Sophia Genetics could be Switzerland's next unicorn". TechCrunch.
  6. ^ Neil, Joshua (16 April 2019). "An Interview with Sophia Genetics: STS and the CE-IVD Designation". Front Line Genomics. Archived from the original on 24 September 2019.
  7. ^ Gaskell, Adi; Wall, Matthew (27 April 2018). "How knowing your genetic code could lengthen your life". BBC News. Retrieved 8 July 2019.
  8. ^ "Genomics testing firm to triple Boston headcount after $110M round". www.bizjournals.com. Retrieved 7 April 2022.
  9. ^ "Sophia genetics". techtour.com. Retrieved 6 May 2022.
  10. ^ Park, Andrea (1 October 2021). "Sophia Genetics teams up with OncoDNA to automate tumor profiling". Fierce Biotech. Retrieved 25 February 2022.
  11. ^ a b Lomas, Natasha (13 September 2017). "Balderton joins $30M Series D for big data biotech platform play, Sophia Genetics". TechCrunch.
  12. ^ Lerivrain, Hélène (25 April 2018). "La biotech suisse Sophia Genetics continue d'investir et s'installe au Pays basque". La Tribune (in French).
  13. ^ Chavanne, Yannick (18 June 2018). "Sophia Genetics rachète un spécialiste mondial de l'exploration de variations génomiques". ICT Journal (in French).
  14. ^ "Swiss company sets up US headquarters in Boston". BostonGlobe.com. 24 September 2018. Retrieved 17 March 2022.
  15. ^ Taylor, Phil (10 August 2020). "Sophia Genetics launches AI tool to find COVID-19 'unknowns' -". pharmaphorum.com. Retrieved 24 March 2022.
  16. ^ Walrath, Rowan (26 July 2021). "Sophia Genetics goes public in $234M IPO, two other biotechs delay". Boston Business Journal. Retrieved 11 December 2024.
  17. ^ Versel, Neil (23 July 2021). "Sophia Genetics Raises $234M in IPO, Eyes Additional Partnerships". GenomeWeb. Retrieved 11 December 2024.
  18. ^ "Illumina, Sophia Genetics to Comarket NGS Solutions for Clinical Dx". GenomeWeb.
  19. ^ "IDT, Sophia Genetics Broaden Partnership to Clinical-Grade Technologies". Clinical OMICs - Molecular Diagnostics in Precision Medicine. 17 January 2020.
  20. ^ "Sophia Genetics, Paragon Genomics Team on SARS-CoV-2 Testing". Clinical OMICs - Molecular Diagnostics in Precision Medicine. 26 March 2020.
  21. ^ "Sophia Genetics to Provide Access to Genomic Analysis Platform to MGI Customers". GenomeWeb.
  22. ^ "Hitachi enters collaboration for data driven precision medicine". www.biospectrumasia.com. Retrieved 28 April 2022.